Dr Reddy's Laboratories

Quick check

The five things to look at first. Open one for more.

• DebtHigh safetyRated AA+ by 2 agencies.
• ResultsProfit fallingIn the Sep 2026 quarter, sales fell 1.5% and profit fell 32% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 27% of the company, about the same as in Sep 2025.
• ValuationExpensive vs its pastThe share trades at 36.6 times its yearly earnings (P/E), pricier than 95% of the time in the last 5 years. Its usual P/E is about 24.

Dr Reddy's Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)36.6 against a typical 33.2: pricier than most peers (1st = cheapest).123rd of 220
• Sales growth−1.5% against a typical +15.6% from a year earlier.151st of 197
• Profit growth−31.7% against a typical +18.9% from a year earlier.122nd of 160
• Share price, 3 months+14.7% against a typical −2%.44th of 200
• Size₹ 1,02,201.8 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).6th of 199

Exchange filings and their impact on the company.

• 23 Oct 2026Outcome of Board MeetingLow impactPositivePrice +6.6% on 26 Oct
  Q2 FY27 results include a small Rs 150.5 cr one-off licence boost, immaterial for full-year scale.

  Dr. Reddy's board on October 23, 2026 approved unaudited Q2 and half-year results for September 30, 2026 under IFRS and Ind AS. Notes disclose Rs 52.9 crore from sale of Bendamustine US territorial rights and Rs 97.6 crore from biosimilar milestones in Russia, totalling Rs 150.5 crore licence income in Global Generics. The amount is a small one-off against annual sales of about Rs 33,700 crore and does not change the underlying business trend.

  Full analysisFiling
• 21 Oct 2026Press ReleaseLow impactPositivePrice +0.2% that day
  DCGI approves Zytorvi for advanced ESCC, its second India indication.

  Dr. Reddy's received DCGI approval for Zytorvi (toripalimab) with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma. This is its second approved use in India after nasopharyngeal carcinoma launched in November 2024. The approval, backed by the Phase 3 JUPITER-06 trial showing 42% risk reduction and median survival of 17.7 vs 12.9 months, expands access to immunotherapy without PD-L1 testing and modestly strengthens its oncology business.

  Full analysisFiling
• 14 Oct 2026General UpdatesLow impactNegativePrice +0.2% on 15 Oct
  USFDA found 3 observations at Dr Reddy's FTO-9 plant, likely causing only a short delay and minor cost.

  USFDA completed a pre-approval inspection on October 8-9, 2026 at Dr Reddy's FTO-9 facility in Visakhapatnam and issued a Form 483 with three observations. The company said it will respond within the stipulated timeline. With no warning letter or import alert, the finding appears routine and addressable, with only a small risk of delay to new approvals from that site.

  Full analysisFiling
• 8 Oct 2026General UpdatesLow impactNegativePrice +1.4% on 9 Oct
  USFDA PAI at FTO-11 ended with 2 observations, a minor remediable finding.

  Dr. Reddy's said the USFDA completed a pre-approval inspection at its FTO-11 plant in Pydibhimavaram from October 5-7, 2026. The agency issued a Form 483 with two observations, which the company will address in time. With only two observations and no warning letter, the finding looks minor and is unlikely to materially affect supplies or approvals over the next year.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Kallam Satish Reddy

Executive Chairman of the Board

Gunupati Venkateswara Prasad

Executive Co-Chairman, Managing Director

Erez Israeli

Chief Executive Officer

Mannam Venkata Narasimham

Chief Financial Officer

Milan Kalawadia

Chief Executive Officer, North America

M. V. Ramana

Chief Executive Officer - Global Generics

Deepak Sapra

Chief Executive Officer - API and Services

Sanjay Sharma

Chief Operating Officer